Insulin Resistance
Search documents
YOUR BODY STORES FAT LIKE THIS 🤯
The Diary Of A CEO· 2025-11-05 20:00
Everybody needs to understand the relationship between sugar, which is glucose, and insulin. When you consume sugar or glucose, the body has to get rid of that glucose very quickly from the bloodstream because glucose actually is toxic inside the bloodstream. I'm consuming glucose and carbs every 2 three hours.I'm stimulating my pancreas. I'm stimulating my insulin. My insulin goes up, it comes down.But before he even gets a chance to come down, it goes up again. So the repeated consumption of and frequent ...
FEMALE HEALTH CRISIS NO ONE IS TALKING ABOUT...
The Diary Of A CEO· 2025-10-27 19:01
Women's Health & Fitness - Muscle mass is crucial for women's brain health by promoting neuron production [1] - Muscle mass correlates with protection as women age, especially important for conditions like PCOS or endometriosis due to its role in fighting insulin resistance and inflammation [2] - Sociocultural assumptions often lead women to focus on weight loss rather than strength and muscle gain, negatively impacting their health [3] - A significant percentage of women, 40% to 50%, face low bone density, contributing to osteoporosis, frailty, and dementia [4] - Hip fractures are disproportionately high in women, with 70% occurring in women, and a 30% mortality rate within one year of the fracture [4] - Health choices based on male data can negatively impact women's hormonal health [4] Emerging Questions & Research Areas - The industry needs to educate women on optimal health practices [5] - Key questions include the best ways to lose weight healthily and diets for fertility [5] - The industry is exploring the link between environmental toxins and early menopause [5] - Research is needed to design perfect workout regimes for menopause and perimenopause [5]
LOSE BELLY FAT BY DOING THIS? 🤯
The Diary Of A CEO· 2025-09-23 12:30
Insulin Resistance & Phenotype - The industry observes that patients with protruding bellies often exhibit insulin resistance due to fat accumulation in the stomach area [1] - The industry notes that individuals with fat concentrated in the stomach may appear healthy from the back but have an increased waist circumference, indicating hyperinsulinemia [1] Impact of Insulin on Weight - The industry suggests that individuals with high insulin levels tend to gain weight easily, such as 5 to 10 pounds after a cruise, because insulin promotes storage [2] - The industry emphasizes that it is difficult for individuals with high insulin levels to lose weight [2] Fasting & Insulin Levels - The industry indicates that fasting is effective in lowering insulin levels, which is crucial for weight loss [2][3] - The industry clarifies that fasting and calorie deficit are not the same thing [2][3] - The industry explains that fasting reduces insulin levels by not stimulating the pancreas [3]
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Globenewswire· 2025-05-01 11:00
Core Insights - Bio-Path Holdings, Inc. has reported promising preclinical results for BP1001-A, indicating its potential to prevent insulin resistance in cells, particularly in the context of obesity and Type 2 diabetes [1][3][5] Group 1: BP1001-A Development - BP1001-A has shown the ability to rescue the decrease in AKT activity in liver cells, which is associated with palmitic acid treatment, suggesting its effectiveness in preventing insulin resistance [1][3] - The drug downregulates Grb2 expression, which is linked to improved insulin signaling in both muscle and liver cell models [3][5] - Bio-Path plans to conduct further preclinical testing using a mouse model to evaluate BP1001-A's impact on weight, insulin sensitivity, and glucose tolerance [4] Group 2: Mechanism of Action - BP1001-A targets the Grb2 protein to enhance insulin sensitivity and lower blood glucose levels in Type 2 diabetes patients [5] - The drug has demonstrated the ability to restore insulin signaling in C2C12 myoblasts, myotubes, and HepG2 liver cells treated with palmitic acid [3][5] Group 3: Future Plans - If preclinical testing is successful, Bio-Path anticipates filing an Investigational New Drug (IND) application in 2025 to initiate a Phase 1 clinical trial [4] - The company is also advancing other product candidates, including BP1002 and BP1003, targeting different proteins for various cancers and metabolic diseases [6]